Abstract
We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine-refractory chronic lymphocytic leukemia. The continuous infusion of alemtuzumab was well tolerated. The typical infusion reaction seen with intravenous alemtuzumab was abolished. Two patients achieved a partial response with an overall response rate of 20%. Alemtuzumab levels were measured in four patients and detectable levels were obtained in three. Clinical activity needs to be confirmed in a larger patient population.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Alemtuzumab
-
Antibodies, Monoclonal / blood
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / blood
-
Antibodies, Neoplasm / therapeutic use*
-
Antineoplastic Agents / therapeutic use
-
Drug Resistance, Neoplasm / drug effects*
-
Female
-
Humans
-
Infusions, Intravenous
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
-
Male
-
Middle Aged
-
Pilot Projects
-
Salvage Therapy*
-
Vidarabine / analogs & derivatives*
-
Vidarabine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Alemtuzumab
-
Vidarabine
-
fludarabine